Reference priceUSD $630.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Loqtorzi |
|---|---|
| Manufacturer | Cohereus BioSciences |
| Prescription required | Yes |
Loqtorzi 40mg/ml injection,1vials x 6ml(toripalimab-tpzi)
toripalimab-tpzi
Description
Loqtorzi 40mg/ml injection,1vials x 6ml(toripalimab-tpzi) is a medicine catalog record in the MediPriceHub database. Active ingredient: toripalimab-tpzi. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Cohereus BioSciences. Therapeutic category: Medicine Library > Oncology Medicines > Nasopharyngeal cancer. Pack information: 240 / 6 (40 / ). Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
LOQTORZI is a programmed death receptor-1 (PD-1)- blocking antibody indicated: in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC) as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapyHow to Use
Use toripalimab-tpzi under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: toripalimab-tpzi. Pack size: 240 / 6 (40 / ). Pack unit: bottle. Manufacturer: Cohereus BioSciences. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Nasopharyngeal cancer. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
The available source record does not provide a clean, product-specific adverse-reaction list. Potential risks depend on the active ingredient, dose, route, treatment duration, and patient condition. Check the approved local prescribing information for the complete adverse-reaction profile, warnings, contraindications, and monitoring requirements. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, serious bleeding, or rapidly worsening symptoms.This information is for reference only. Consult a qualified healthcare professional before using any medicine.